Screener
UroGen Pharma URGN Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $79,133 | $110,745 |
| Marketable securities | 28,842 | 9,711 |
| Restricted cash | 1,329 | 1,350 |
| Accounts receivable, net | 88,757 | 33,082 |
| Inventories | 24,589 | 16,464 |
| Prepaid expenses and other current assets | 12,776 | 14,672 |
| Total current assets | 235,426 | 186,024 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's restricted cash?
- UroGen Pharma (URGN) reported restricted cash of $1.33M in Q2 2026.
- How has UroGen Pharma's restricted cash changed year-over-year?
- UroGen Pharma's restricted cash increased by 22.8% year-over-year, from $1.08M to $1.33M.
- What is the long-term trend for UroGen Pharma's restricted cash?
- Over 5 years (2020 to 2025), UroGen Pharma's restricted cash has grown at a 1.9% compound annual growth rate (CAGR), from $1.23M to $1.35M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about UroGen Pharma's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude